59
Participants
Start Date
May 31, 2010
Primary Completion Date
August 31, 2015
Study Completion Date
February 28, 2017
Bendamustine
Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
Bortezomib
"1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.~Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15"
Dexamethasone
20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
Center for Cancer and Blood Disorders, Bethesda
National Capital Clinical Research Consortium, Bethesda
Peninsula Cancer Institute, Newport News
South Carolina Oncology Associates, Columbia
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Oncology Hematology Care Inc., Cincinnati
Grand Rapids Clinical Oncology Program, Grand Rapids
Hematology Oncology Clinic, LLP, Baton Rouge
Leading Edge Research, PA, Arlington
The Center for Cancer and Blood Disorders, Fort Worth
Los Robles Hospital and Medical Center, Thousand Oaks
Collaborators (2)
Millennium Pharmaceuticals, Inc.
INDUSTRY
Cephalon
INDUSTRY
SCRI Development Innovations, LLC
OTHER